Secondary outcome was EEG theta/gamma ratio. Primary clinical outcomes were memory and global cognition, measured with the Memory Index Score (MIS) and Montreal Cognitive Assessment (MoCA), respectively. Primary outcomes were safety, as determined by the reporting of side effects and adverse events, and feasibility, as determined by adherence and compliance with the study protocol.
Finally, in the Taper phase, participants received 2–3 sessions per week over 3-months. Subsequently, participants completed a 2–3-month Hiatus Phase not receiving HB-tACS. Three participants underwent resting state electroencephalography (EEG) before and after the 14-week Acute Phase. The Acute Phase comprised 14-weeks of HB-tACS with at least five sessions per week. Methods: Eight participants diagnosed with AD underwent multiple consecutive sessions of high-definition HB-tACS (40 Hz, 20-min) targeting the left angular gyrus (AG), a key node of the memory network. Here we investigate the feasibility, safety, and preliminary effects on episodic memory of an innovative protocol where tACS is administered within the homes of older adults with AD with the help of a study companion (HB-tACS). Recently, transcranial alternating current stimulation (tACS) has shown memory improvement in AD by normalizing high-frequency neuronal activity. Current pharmacological treatments have limited efficacy. 9Department of Medicine, Harvard Medical School, Boston, MA, United Statesīackground: Over 55 million people worldwide are currently diagnosed with Alzheimer’s disease (AD) and live with debilitating episodic memory deficits.8Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Spain.7Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.6Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.5Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.4Institut Guttmann, Institut Universitari de Neurorehabilitació Adscrit a la UAB, Barcelona, Spain.3Department of Neurology, Harvard Medical School, Boston, MA, United States.
2Deanna and Sidney Wolk Center for Memory Health at Hebrew SeniorLife, Boston, MA, United States.1Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, Boston, MA, United States.Davide Cappon 1,2,3*, Rachel Fox 1,2, Tim den Boer 1, Wanting Yu 1, Nicole LaGanke 1, Gabriele Cattaneo 4,5,6, Ruben Perellón-Alfonso 7,8, David Bartrés-Faz 7,8, Brad Manor 1,9 and Alvaro Pascual-Leone 1,2,3
0 kommentar(er)
